MAPT and amyloidosis: To investigate whether introduction of the Christchurch variant into mAPOE affects development of AD-like pathologies, while distinguishing between amyloid- and tau-dependent effects, we independently crossed ApoeCh mice with the 5xFAD amyloidosis mouse model [25, 43, 44] (Fig. 1c), and the PS19 tauopathy mouse model [45–47] (Fig. 1d; data from Figs. 4, 5, 6, 7 and 8).